

This promotional meeting has been organised and funded by Takeda and is intended for UK healthcare professionals. Prescribing and adverse event reporting information can be found at the bottom of the page.



Exploring FRUZAQLA use in UK Real World Practice in 3L+ mCRC

Thursday 11th June 2026, 17:30 - 18:30 BST
Harrogate Convention Centre, Harewood 2, Crowne Plaza

Join us for what we hope will be an insightful session exploring FRUZAQLA in UK real world practice, discussing the recent evolution of the treatment landscape, practical considerations around AE management and dosing, followed by a case study session on utilising FRUZAQLA in the 3L+ setting in mCRC.

Come listen, share insights, and connect with colleagues as we discuss how to work together to improve outcomes for patients with late-stage CRC.
We look forward to seeing you there!

This session will include valuable insights from our speakers



Prof. Richard Adams
Consultant Clinical Oncologist
Velindre Cancer Centre



Ms Rhian Jones
Advanced Nurse Practitioner
The Christie NHS FT



Dr Kalena Marti
Consultant Medical Oncologist
The Christie NHS FT



Dr Khurum Khan
Consultant Medical Oncologist
University College London
Hospitals NHS FT

Agenda

Welcome and Introduction	Prof. Richard Adams
3L+ mCRC Today: Recent Evolution of the Treatment Landscape	Prof. Richard Adams
The Christie Experience: Practical considerations and learnings from using FRUZAQLA	Dr. Kalena Marti Ms. Rhian Jones
Personalized Decision-Making in 3L+ mCRC: Insights from UCLH	Dr. Khurum Khan
Panel Discussion and Q&A	All Speakers

FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and, if RAS wildtype and medically appropriate, an anti-EGFR therapy.¹

3L = third line CRC = colorectal cancer mCRC = metastatic colorectal cancer

References: 1. FRUZAQLA summary of product characteristics

Click [here](#) to access FRUZAQLA prescribing information

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com

